Cintodac 10 Capsules

babies: it is not applicable. lactating mother: consult your doctor before using this medication in breastfeeding.
pregnancy: consult your doctor before using this medication in pregnancy. alcohol: caution is advised while drinking alcohol with cinitapride, pantoprazole sodium.
driving: cinitapride, pantoprazole sodium capsule may cause dizziness, and it may alter your ability to drive. kidney: limited information is only available on the use of cinitapride, pantoprazole sodium capsules in patients with kidney disease.
consult your doctor before using this medication. liver: cinitapride, a pantoprazole sodium capsule, is considered safe to use in patients with liver disease.
dose adjustment is not required. consult your doctor..

Headache Diarrhea Stomach pain Flatulence Dizziness.

cintodac is a gastroprokinetic agent. it works by enhancing the release of a chemical messenger (acetylcholine), which increases bowel movements and decreases abdominal pain or discomfort.
pantoprazole is a proton pump inhibitor. it works by decreasing the amount of acid in your stomach and provides relief from indigestion and heartburn..

If you miss a dose, take it as soon as possible. If it is near the time of next dose, then skip the missed dose. Take the next dose at on your regular time. Don't double the dose to catch up missed dose..

• cintodac capsule is used in the treatment of gastroesophageal reflux disease and peptic ulcer disease • it is better to take on an empty stomach • inform your doctor if you experience watery diarrhoea, fever, or stomach pain for an extended time period • avoid consuming alcohol while taking this medication because it may increase the risk of stomach damage • you are advised to take a calcium-rich diet and vitamin d supplements • do not use it for a longer time unless prescribed by your doctor • prolonged use of this medication may cause weak or broken bones.

• pantoprazole sodium + rilpivirine: concurrent use may result in reduced rilpivirine plasma concentrations and risk of diminished therapeutic effect of rilpivirine • pantoprazole sodium + amphetamine: concurrent use may result in increased exposure to amphetamine • pantoprazole sodium + citalopram: concurrent use may result in increased citalopram exposure and risk of qt-interval prolongation • pantoprazole sodium + ketoconazole: concurrent use may result in decreased ketoconazole exposure • pantoprazole sodium + ampicillin: concurrent use may result in loss of ampicillin efficacy • cinitapride + acenocoumarol: concurrent use may result in increased risk or severity of adverse effects of cinitapride • cinitapride + ambrisentan: concurrent use may result in a decrease in the antihypertensive activities of ambrisentan • cinitapride + antipyrine: concurrent use may result in an increased risk of hypertension • cinitapride + amphetamine: concurrent use may result in an increased risk of serotonin syndrome • cinitapride + brimonidine: concurrent use may result in increased cns depressant.